Rehabilitation

Phoenix Holdings Publishes Financial Statements for Q4 and 2023

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Business, Insurance, Finance, Asset Management, Consulting, Banking, Friends, The Phoenix Companies, Growth, Memory, Share repurchase, Corporation, Policy, TLV, Acquisition, Tel Aviv Stock Exchange, Life, Credit, Solvency, Asset management, Report, SME, Analyst, Safety, Barzilai Medical Center, P&C, Holding, Collection, Pain, Rehabilitation, Mobile phone

Phoenix Holdings Ltd., a leading Israel-based financial, insurance, and investment group (TLV:PHOE) (“Phoenix,” the “Group,” or the “Company”), today reported its results for the fourth quarter of 2023 and calendar year 2023.

Key Points: 
  • Phoenix Holdings Ltd., a leading Israel-based financial, insurance, and investment group (TLV:PHOE) (“Phoenix,” the “Group,” or the “Company”), today reported its results for the fourth quarter of 2023 and calendar year 2023.
  • Phoenix is financially resilient with high levels of liquidity and a high Solvency II ratio for Phoenix Insurance, which reached 209% with transitional measures as of September 30, 2023.
  • Comprehensive income before tax in 2023 amounted to NIS 241 million, compared to NIS 235 million in 2022.
  • Comprehensive income before tax in 2023 amounted to NIS 307 million, compared to NIS 300 million in 2022.

Federal Home Loan Bank of Dallas and Wells Fargo Bank Award $750K to CC Housing for Senior Affordable Housing Development

Retrieved on: 
Wednesday, March 27, 2024
Construction & Property, Seniors, Finance, Banking, Professional Services, Philanthropy, Consumer, Foundation, Other Philanthropy, Residential Building & Real Estate, Health, Substance abuse, CC, AHP, Catholic Charities USA, Investment, Felician Sisters, Housing, FHLB, Federal Home Loan Banks, Wells Fargo, Multimedia, Catholic Church, Rehabilitation, Real estate

FHLB Dallas awarded a $750,000 Affordable Housing Program (AHP) grant through member Wells Fargo to CC Housing to assist with construction.

Key Points: 
  • FHLB Dallas awarded a $750,000 Affordable Housing Program (AHP) grant through member Wells Fargo to CC Housing to assist with construction.
  • (Photo: Business Wire)
    CC Housing, a housing nonprofit organization based in Albuquerque, New Mexico, provides affordable housing options to low-income and special-needs families and individuals across New Mexico.
  • AHP funds assist FHLB Dallas members in financing the purchase, construction and rehabilitation of owner-occupied, rental or transitional housing and housing for homeless individuals.
  • “Wells Fargo has been instrumental in affordable housing developments in areas that need it most,” said Greg Hettrick, senior vice president and director of Community Investment at FHLB Dallas.

EverEx Secures iF Design Award for “MORA,” a Leading Musculoskeletal Rehabilitation Solution

Retrieved on: 
Thursday, March 28, 2024
Apps, Applications, Technology, Medical Devices, Professional Services, Software, Start-Up, Other Health, Physical Therapy, Health, Artificial Intelligence, Single-frequency network, Attention, Rehabilitation, IDE, MFDS, Patellofemoral pain syndrome, Clinical trial, DSM-IV codes, CES, FDA, RTM

EverEx, a musculoskeletal digital healthcare startup in South Korea, has been honored with the world-renowned design prize, the iF Design Award.

Key Points: 
  • EverEx, a musculoskeletal digital healthcare startup in South Korea, has been honored with the world-renowned design prize, the iF Design Award.
  • Organized annually by the Hannover-based iF International Forum Design GmbH, the iF Design Award is highly revered in the design community.
  • This accolade, following closely after the CES 2024 Innovation Award win in digital healthcare, further cements EverEx's position as a leader in musculoskeletal rehabilitation.
  • Dr. Chan Yoon, CEO of EverEx, commented, “Winning the iF Design Award underscores our commitment to enhancing the efficiency and accessibility of rehabilitation practices through digital innovation.

Panish | Shea | Ravipudi LLP Obtains an $11 Million Jury Verdict for a Motorcyclist Struck by a City of Los Angeles DWP Vehicle

Retrieved on: 
Monday, March 25, 2024
Legal, Professional Services, General counsel, Pelvis, Crash, Travel, City, LLP, County, Water, Injury, Superior court, DWP, Rib, Pain, Wrist, Rehabilitation

A Los Angeles County Superior Court jury in Van Nuys has awarded $11,045,000 to a motorcyclist who suffered serious injuries following a collision with a Los Angeles Department of Water and Power (DWP) vehicle.

Key Points: 
  • A Los Angeles County Superior Court jury in Van Nuys has awarded $11,045,000 to a motorcyclist who suffered serious injuries following a collision with a Los Angeles Department of Water and Power (DWP) vehicle.
  • Plaintiff was represented at trial by Robert Glassman, Tom Schultz, and Jonathan Davidi of Panish | Shea | Ravipudi LLP .
  • "The City of Los Angeles Department of Water and Power fought us every step of the way," said Robert Glassman, partner at Panish | Shea | Ravipudi LLP.
  • We are thankful the jury got it right and delivered a just verdict based on the evidence and their common sense."

Italfarmaco Receives FDA Approval for Duvyzat™ (givinostat) in Duchenne Muscular Dystrophy

Retrieved on: 
Friday, March 22, 2024
Research, FDA, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, HDAC, ITF, MAA, The Lancet, Caregiver, Disease, Magnetic resonance imaging, PPMD, Patient, Rehabilitation, Lancet Neurology, University, EMA, Doctor of Philosophy, MD, Duchenne muscular dystrophy, Pediatrics, Therapy, NSAA, DMD, Food, Pharmaceutical industry

“We are grateful for the support of those living with DMD and their dedicated caregivers, which played a central role in helping us reach this landmark FDA approval.

Key Points: 
  • “We are grateful for the support of those living with DMD and their dedicated caregivers, which played a central role in helping us reach this landmark FDA approval.
  • The FDA approval highlights the dedication of Italfarmaco’s research and clinical teams to achieve this milestone for the company.”
    The approval is based on the results of the pivotal multicentre, randomised, double-blind, placebo-controlled phase 3 EPIDYS trial ( NCT02851797 ).
  • Italfarmaco has significantly expanded its U.S. presence through the formation of a new fully owned subsidiary, ITF Therapeutics LLC.
  • Italfarmaco has a global presence and is also working with other regulatory agencies.

$1 Million to Benefit Red Lake Reservation Housing Authority Through Federal Home Loan Bank of Des Moines’ Affordable Housing Program

Retrieved on: 
Wednesday, March 20, 2024
Commercial Building & Real Estate, Construction & Property, Finance, Banking, Professional Services, Philanthropy, Fund Raising, Foundation, Residential Building & Real Estate, Red Lake Indian Reservation, Organization, AHP, Partnership, Alaska Natives, Meta, Economic development, Native, Private sector, Insurance, Federal Home Loan Banks, Housing, FHLB, Multimedia, Rehabilitation, Bank

The Federal Home Loan Bank of Des Moines (FHLB Des Moines) partnered with its member First National Bank Bemidji to award Red Lake Reservation Housing Authority (RLRHA) a $1 million grant to support the construction of nearly 30 new three-bedroom single-family units on the Red Lake Reservation in Minnesota.

Key Points: 
  • The Federal Home Loan Bank of Des Moines (FHLB Des Moines) partnered with its member First National Bank Bemidji to award Red Lake Reservation Housing Authority (RLRHA) a $1 million grant to support the construction of nearly 30 new three-bedroom single-family units on the Red Lake Reservation in Minnesota.
  • View the full release here: https://www.businesswire.com/news/home/20240320834034/en/
    The Federal Home Loan Bank of Des Moines partnered with its member First National Bank Bemidji to award Red Lake Reservation Housing Authority a $1 million grant to support new housing on the Red Lake Reservation in Minnesota.
  • (Photo: Business Wire)
    Red Lake Reservation is owned and occupied entirely by members of the Red Lake Band of Chippewa Indians — the only such reservation in Minnesota.
  • The proposed project units will be located in four communities on the Red Lake Reservation: Red Lake, Little Rock, Redby and Ponemah.

Results from Italfarmaco Pivotal Phase 3 EPIDYS Study of Givinostat in Duchenne Muscular Dystrophy (DMD) Published in The Lancet Neurology

Retrieved on: 
Tuesday, March 19, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Hospitals, Genetics, Clinical Trials, VL, Civil service commission, Givinostat, Neurology, Catholic higher education, Diarrhea, MAA, The Lancet, Magnetic resonance imaging, Safety, Abdominal pain, NDA, Manuscript, Rehabilitation, Lancet Neurology, University, OLE, EMA, Degenerative disease, Doctor of Philosophy, MD, European Medicines Agency, Duchenne muscular dystrophy, European Commission, NSAA, FDA, DMD, Pediatrics, PDUFA, Pharmaceutical industry

Italfarmaco S.p.A. announced today that the full results from the Company’s pivotal phase 3 EPIDYS clinical trial with givinostat in ambulant boys 6 years of age and older with Duchenne muscular dystrophy (DMD) have been published in The Lancet Neurology.

Key Points: 
  • Italfarmaco S.p.A. announced today that the full results from the Company’s pivotal phase 3 EPIDYS clinical trial with givinostat in ambulant boys 6 years of age and older with Duchenne muscular dystrophy (DMD) have been published in The Lancet Neurology.
  • The full manuscript, titled, “Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial,” is published on The Lancet Neurology website .
  • Participants attended study site visits every 12 weeks for 72 weeks and were evaluated for all endpoints within the study protocol.
  • Upon completion of the 18-month double-blind period, EPIDYS study participants were eligible to enroll in an open-label extension study (OLE study) to receive givinostat on an ongoing basis.

Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up

Retrieved on: 
Tuesday, March 19, 2024
Health, Medical Devices, Other Health, Clinical Trials, Research, Science, Biotechnology, Disability, Patient, Nature, Insurance, Back pain, Pain, Multimedia, Rehabilitation

Mainstay Medical Holdings plc today announced the publication of the 5-year follow up from the ReActiv8-B randomized, sham-controlled, double-blinded trial.

Key Points: 
  • Mainstay Medical Holdings plc today announced the publication of the 5-year follow up from the ReActiv8-B randomized, sham-controlled, double-blinded trial.
  • ReActiv8 is the only restorative therapy for patients suffering from non-surgical, mechanical CLBP evidenced by multifidus dysfunction.
  • View the full release here: https://www.businesswire.com/news/home/20240319164677/en/
    The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs.
  • (Graphic: Business Wire)
    The publication is available here:
    The ReActiv8-B study saw multiple patients have their implants removed for resolution of back pain.

Small Door Opens First Maryland Practice With New Bethesda Location

Retrieved on: 
Monday, March 18, 2024
Other Consumer, Other Health, Retail, Pets, Other Professional Services, Telemedicine, Virtual Medicine, Urban Planning, Family, Consumer, Other Construction & Property, Professional Services, Department Stores, Practice Management, Veterinary, Commercial Building & Real Estate, Construction & Property, Other Retail, Health, AAHA, Internal medicine, American Animal Hospital Association, Dentistry, Entrepreneurship, Humane society, Partnership, Patient, Accreditation, Animal science, Madeira School, University, Veterinary medicine, Telehealth, Federal Realty Investment Trust, Wildwood, Public, Dermatology, Infection, B Corporation (certification), Pain management, Missouri College, Pet, CCRP, Rehabilitation

Small Door Inc., a tech-enabled, membership-based veterinary care provider that operates under the brand Small Door Veterinary , today opened its first location in Maryland and will now be accepting new members at its state-of-the-art practice in Bethesda (10253 Old Georgetown Rd).

Key Points: 
  • Small Door Inc., a tech-enabled, membership-based veterinary care provider that operates under the brand Small Door Veterinary , today opened its first location in Maryland and will now be accepting new members at its state-of-the-art practice in Bethesda (10253 Old Georgetown Rd).
  • The new facility, located in the Wildwood Shopping Center, is the fourth location to open in the DMV (District of Columbia, Maryland, and Virginia), as Small Door continues to address a growing need for veterinary medicine amongst local pet owners.
  • The opening marks the eleventh Small Door location overall, continuing a steady expansion plan.
  • Launching at Wildwood Shopping Center continues our strategic rollout across the Greater Washington market,” explained Josh Guttman, Co-Founder and CEO of Small Door.

Neurolutions, Inc. Announces Groundbreaking CMS Decision for IpsiHand™: A Leap Forward in Stroke Rehabilitation

Retrieved on: 
Tuesday, March 12, 2024
Health, Hospitals, Neurology, Health Technology, Practice Management, Physical Therapy, HCPCS, Durable medical equipment, Brain, BCI, Patient, DME, Stroke, Classification, Survivor, Medicare, FDA, CMS, Movement, Rehabilitation, Medical device

E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.

Key Points: 
  • E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.
  • The IpsiHand System is a breakthrough therapeutic device and the only FDA-cleared, commercially available solution that enables non-invasive, at-home rehabilitation for stroke survivors affected by chronic motor deficits.
  • CMS’ decision also includes a final Medicare benefit category determination, classifying the IpsiHand as Durable Medical Equipment (DME).
  • Neurolutions is proud to partner with CMS to advance the forefront of the rapidly-growing frontier of BCI enabled post-stroke neurorehabilitation.